Clinical trial NCT03246347: A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Official title: A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Prostate Cancer
Prostate Adenocarcinoma
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
Collaborators: name: Astellas Pharma Inc
name: Medivation, Inc.
First posted: 2017-08-11
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.

Detailed description: This is a single center, single arm, phase II trial designed to evaluate the 12 month PSA complete response rate in patients with metastatic hormone sensitive prostate cancer treated with ADT, docetaxel and enzalutamide. The primary endpoint of this study will be 12-month PSA complete response rate, which will be assessed against a contemporary historical control rate for the combination of ADT and docetaxel alone in the metastatic hormone naive setting. The study will be conducted at all participating sites across North and South Carolina within the Levine Cancer Institute network. Enrollment is anticipated to be completed within 24 months.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the prostate without evidence of small cell carcinoma or greater than 50% neuroendocrine differentiation. Metastatic disease must be present including soft tissue, and/or bone metastases OR nonregional lymph node involvement prior to study enrollment. If the subject has regional lymph node involvement, there must be at least one additional site of disease including visceral, non-regional nodal or skeletal metastases.
* ADT with surgical castration with bilateral orchiectomy or medical castration with LHRH agonist or LHRH antagonist therapy may have been initiated no greater than 112 days (16 weeks) prior to enrollment date. Subjects who initiated ADT prior to consent, are not eligible if PSA has risen ≥ 25% and ≥ 2 ng/ml above nadir value since initiation of ADT prior to consent.
* At least one PSA level of ≥ 5 ng/ml within 90 days prior to consent.
* Prior ADT for non-metastatic disease with LHRH agonist or LHRH antagonist therapy in the neoadjuvant/adjuvant setting is permitted if:

  1. Total duration of therapy did not exceed 36 months
  2. 6 months have elapsed since completion of therapy prior to consent,
  3. Serum testosterone \> 50 ng/dl within 28 days prior to reinitiation of ADT for metastatic disease
  4. Prior ADT for non-metastatic disease must have accompanied definitive local therapy for curative intent.
* Age ≥ 18 years.
* ECOG performance status 0-2.
* Adequate liver function: AST and ALT \<1.5x upper limit of normal, total bilirubin \< 1x upper limit of normal.
* Adequate bone marrow function: Platelets \>100,000 cells/mm3, Hemoglobin \> 8.0g/dL and ANC \> 1,500 cells/mm3.
* Adequate renal function with a creatinine clearance (based on Cockcroft-Gault formula) ≥ 30 mL/min.
* Ability to understand and the willingness to sign a written informed consent document.
* Able to swallow and retain oral medication

Exclusion Criteria:

* Personal history of seizure.
* Personal history of conditions that may predispose to seizure activity including cortical cerebrovascular accident or brain trauma.
* Known central nervous system metastases, including involvement of brain parenchyma and leptomeninges.
* Personal history of any condition that may impair absorption of enzalutamide.
* Prior or current therapy with ketoconazole, abiraterone, enzalutamide, apalutamide (ARN-509, JNJ-56021927), darolutamide (ODM-201, BAY1841788) or cytotoxic chemotherapy such as docetaxel, cabazitaxel, cyclophosphamide.
* Prior therapy with bicalutamide, nilutamide or flutamide within 14 days of enrollment.
* Within 28 days of major surgery and/or lack of recovery from prior surgical procedure or 14 days of palliative radiation prior to enrollment.
* Prior or current therapy with an investigational agent for metastatic prostate cancer.
* Known hypersensitivity to drugs formulated with polysorbate 80.
* Personal history of posterior reversible encephalopathy syndrome.
* CTCAE version 4.0 grade 2-4 peripheral sensory neuropathy.
* Human immunodeficiency virus infection or active hepatitis B or C infection.
* Uncontrolled and current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator.
* Presence of any of the following within the previous 3 months prior to enrollment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.
* History of an additional active malignancy within 12 months prior to the date of consent (except non-melanoma skin cancer).
* Current use of strong CYP2C8 inhibitors, CYP3A4 inducers or CYP3A4, CYP2C9 or CYP2C19 substrates with a narrow therapeutic range as listed in Section 7.2.1.
* Any condition that requires the use of prednisone \> 10mg daily, or equivalent daily glucocorticoid dose, for greater than 14 days

Primary outcomes:
measure: 52-week PSA Complete Response (CR) Rate
timeFrame: 52 weeks
Secondary outcomes:
measure: Serologic Response Rate
timeFrame: Duration of study participation, an average of 2 years
measure: Radiographic Response Rate
timeFrame: Duration of study participation, an average of 2-3 years
measure: Time to Castrate Resistance
timeFrame: Duration of study participation, an average of 2 years
measure: Serologic Progression Free Survival
timeFrame: Duration of study participation, an average of 2 years
measure: Radiographic Progression Free Survival
timeFrame: Duration of study participation, an average of 2-3 years
measure: Overall Survival
timeFrame: Duration of study participation, an average of 5 years
measure: Time to Treatment Failure
timeFrame: Duration of study participation, an average of 2-3 years
measure: Treatment-related Adverse Events as Assessed by CTCAE v4.0
timeFrame: Duration of study participation, an average of 5 years
Other outcomes:
Locations:
city: Charlotte
country: United States
facility: Levine Cancer Institute
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Earle Burgess, MD
role: PRINCIPAL_INVESTIGATOR
References: